TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibod...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research : BCR Vol. 22; no. 1; p. 22
Main Authors Vaklavas, Christos, Roberts, Brian S, Varley, Katherine E, Lin, Nancy U, Liu, Minetta C, Rugo, Hope S, Puhalla, Shannon, Nanda, Rita, Storniolo, Anna Maria, Carey, Lisa A, Saleh, Mansoor N, Li, Yufeng, Delossantos, Jennifer F, Grizzle, William E, LoBuglio, Albert F, Myers, Richard M, Forero-Torres, Andres
Format Journal Article
LanguageEnglish
Published England BioMed Central 18.02.2020
BMC
Subjects
Angiogenesis
Antitumor activity
Bevacizumab
Biopsy
Blood
Breast cancer
Cancer therapies
Consent
Disease
Endocrine therapy
ErbB-2 protein
Estrogens
Headache
Hormone receptor-positive breast cancer
Hypotheses
Immunotherapy
Letrozole
Luminal breast cancer
Lymphatic system
Magnetic resonance imaging
Mammography
Medical research
Monoclonal antibodies
Patients
Post-menopause
Preoperative therapy
Progesterone
Proteinuria
Remission
Ribonucleic acid
RNA
Surgery
Targeted cancer therapy
Toxicity
Tumors
Ultrasonic imaging
Urine
Vascular endothelial growth factor
Womens health
United States > US
Postmenopausal
Preoperative therapy
Hormone receptor-positive breast cancer
Breast cancer
Letrozole
Bevacizumab
Luminal breast cancer
Online AccessGet full text

Cover

Abstract In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and downstaging rate. Seventy-five patients were randomized (Let/Bev n = 50, Let n = 25). Of the 45 patients evaluable for pathological response in the Let/Bev arm, 5 (11%; 95% CI, 3.7-24.1%) achieved pCR and 4 (9%; 95% CI, 2.5-21.2%) had microscopic residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0-14.2%). The rates of downstaging were 44.4% (95% CI, 29.6-60.0%) and 37.5% (95% CI, 18.8-59.4%) in the Let/Bev and Let arms, respectively. Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3 and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and confirmed on an independent cohort. In the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%; no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy. This trial is registered with ClinicalTrials.gov (Identifier: NCT00161291), first posted on September 12, 2005, and is completed.
AbstractList Abstract Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. Methods Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and downstaging rate. Results Seventy-five patients were randomized (Let/Bev n  = 50, Let n  = 25). Of the 45 patients evaluable for pathological response in the Let/Bev arm, 5 (11%; 95% CI, 3.7–24.1%) achieved pCR and 4 (9%; 95% CI, 2.5–21.2%) had microscopic residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0–14.2%). The rates of downstaging were 44.4% (95% CI, 29.6–60.0%) and 37.5% (95% CI, 18.8–59.4%) in the Let/Bev and Let arms, respectively. Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3 and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and confirmed on an independent cohort. Conclusion In the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%; no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy. Trial registration This trial is registered with ClinicalTrials.gov (Identifier: NCT00161291 ), first posted on September 12, 2005, and is completed.
Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. Methods Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and downstaging rate. Results Seventy-five patients were randomized (Let/Bev n = 50, Let n = 25). Of the 45 patients evaluable for pathological response in the Let/Bev arm, 5 (11%; 95% CI, 3.7–24.1%) achieved pCR and 4 (9%; 95% CI, 2.5–21.2%) had microscopic residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0–14.2%). The rates of downstaging were 44.4% (95% CI, 29.6–60.0%) and 37.5% (95% CI, 18.8–59.4%) in the Let/Bev and Let arms, respectively. Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3 and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and confirmed on an independent cohort. Conclusion In the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%; no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy. Trial registration This trial is registered with ClinicalTrials.gov (Identifier: NCT00161291), first posted on September 12, 2005, and is completed.
BACKGROUNDIn preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. METHODSPostmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and downstaging rate. RESULTSSeventy-five patients were randomized (Let/Bev n = 50, Let n = 25). Of the 45 patients evaluable for pathological response in the Let/Bev arm, 5 (11%; 95% CI, 3.7-24.1%) achieved pCR and 4 (9%; 95% CI, 2.5-21.2%) had microscopic residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0-14.2%). The rates of downstaging were 44.4% (95% CI, 29.6-60.0%) and 37.5% (95% CI, 18.8-59.4%) in the Let/Bev and Let arms, respectively. Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3 and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and confirmed on an independent cohort. CONCLUSIONIn the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%; no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy. TRIAL REGISTRATIONThis trial is registered with ClinicalTrials.gov (Identifier: NCT00161291), first posted on September 12, 2005, and is completed.
Abstract Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. Methods Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and downstaging rate. Results Seventy-five patients were randomized (Let/Bev n = 50, Let n = 25). Of the 45 patients evaluable for pathological response in the Let/Bev arm, 5 (11%; 95% CI, 3.7–24.1%) achieved pCR and 4 (9%; 95% CI, 2.5–21.2%) had microscopic residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0–14.2%). The rates of downstaging were 44.4% (95% CI, 29.6–60.0%) and 37.5% (95% CI, 18.8–59.4%) in the Let/Bev and Let arms, respectively. Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3 and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and confirmed on an independent cohort. Conclusion In the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%; no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy. Trial registration This trial is registered with ClinicalTrials.gov (Identifier: NCT00161291 ), first posted on September 12, 2005, and is completed.
In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies. This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole enhanced the antitumor activity of the letrozole in the preoperative setting. Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and downstaging rate. Seventy-five patients were randomized (Let/Bev n = 50, Let n = 25). Of the 45 patients evaluable for pathological response in the Let/Bev arm, 5 (11%; 95% CI, 3.7-24.1%) achieved pCR and 4 (9%; 95% CI, 2.5-21.2%) had microscopic residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0-14.2%). The rates of downstaging were 44.4% (95% CI, 29.6-60.0%) and 37.5% (95% CI, 18.8-59.4%) in the Let/Bev and Let arms, respectively. Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3 and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and confirmed on an independent cohort. In the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%; no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy. This trial is registered with ClinicalTrials.gov (Identifier: NCT00161291), first posted on September 12, 2005, and is completed.
ArticleNumber 22
Author Rugo, Hope S
Vaklavas, Christos
Carey, Lisa A
Roberts, Brian S
Saleh, Mansoor N
Lin, Nancy U
Nanda, Rita
Delossantos, Jennifer F
Storniolo, Anna Maria
Liu, Minetta C
Grizzle, William E
LoBuglio, Albert F
Puhalla, Shannon
Myers, Richard M
Varley, Katherine E
Forero-Torres, Andres
Li, Yufeng
Author_xml – sequence: 1
  givenname: Christos
  orcidid: 0000-0002-9919-2748
  surname: Vaklavas
  fullname: Vaklavas, Christos
  organization: Present Address: Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
– sequence: 2
  givenname: Brian S
  surname: Roberts
  fullname: Roberts, Brian S
  organization: HudsonAlpha, Institute for Biotechnology, Huntsville, AL, USA
– sequence: 3
  givenname: Katherine E
  surname: Varley
  fullname: Varley, Katherine E
  organization: HudsonAlpha, Institute for Biotechnology, Huntsville, AL, USA
– sequence: 4
  givenname: Nancy U
  surname: Lin
  fullname: Lin, Nancy U
  organization: Dana-Farber Cancer Institute, Boston, MA, USA
– sequence: 5
  givenname: Minetta C
  surname: Liu
  fullname: Liu, Minetta C
  organization: Lombardi Cancer Center, Georgetown University Hospital, Washington, DC, USA
– sequence: 6
  givenname: Hope S
  surname: Rugo
  fullname: Rugo, Hope S
  organization: Hellen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
– sequence: 7
  givenname: Shannon
  surname: Puhalla
  fullname: Puhalla, Shannon
  organization: University of Pittsburgh Medical Center, Magee Women's Cancer Program, Pittsburgh, PA, USA
– sequence: 8
  givenname: Rita
  surname: Nanda
  fullname: Nanda, Rita
  organization: University of Chicago, Chicago, IL, USA
– sequence: 9
  givenname: Anna Maria
  surname: Storniolo
  fullname: Storniolo, Anna Maria
  organization: Melvin and Bren Simon Cancer Center at Indiana University, Indianapolis, IN, USA
– sequence: 10
  givenname: Lisa A
  surname: Carey
  fullname: Carey, Lisa A
  organization: University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
– sequence: 11
  givenname: Mansoor N
  surname: Saleh
  fullname: Saleh, Mansoor N
  organization: Georgia Cancer Specialists PC, Atlanta, GA, USA
– sequence: 12
  givenname: Yufeng
  surname: Li
  fullname: Li, Yufeng
  organization: University of Alabama at Birmingham, Birmingham, AL, USA
– sequence: 13
  givenname: Jennifer F
  surname: Delossantos
  fullname: Delossantos, Jennifer F
  organization: University of Alabama at Birmingham, Birmingham, AL, USA
– sequence: 14
  givenname: William E
  surname: Grizzle
  fullname: Grizzle, William E
  organization: University of Alabama at Birmingham, Birmingham, AL, USA
– sequence: 15
  givenname: Albert F
  surname: LoBuglio
  fullname: LoBuglio, Albert F
  organization: University of Alabama at Birmingham, Birmingham, AL, USA
– sequence: 16
  givenname: Richard M
  surname: Myers
  fullname: Myers, Richard M
  organization: HudsonAlpha, Institute for Biotechnology, Huntsville, AL, USA
– sequence: 17
  givenname: Andres
  surname: Forero-Torres
  fullname: Forero-Torres, Andres
  email: aforero@seagen.com
  organization: University of Alabama at Birmingham, Birmingham, AL, USA. aforero@seagen.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32070401$$D View this record in MEDLINE/PubMed
BookMark eNpdUk1v1DAQjVAR_YA_wAFZ4sKhoY4TxwkHJFgVulIlpKpI3KyJPdl1ldjBdvr1U_k1eHdL1eLLjMdvnt-M3mG2Z53FLHtb0I9F0dQnoSgpb3LKaE4LlrLbF9lBUdU85xX7tfck388OQ7iitBANb15l-yWjgla0OMj-XH5dXCwIpewTATKtISBZLo-JB6vdaO5RHxM3oc0H6HAg0RsYiOvJ5DGVPURzjWTA6N29G5DcmLgmzm-jmyPp8BqUuZ9H6IixZHIhjmjdBHNIPDcuXXY9Fm-GO6INrKwLqEmIsELCTkqydn5McxOPCqfofJ5IzPbbJJGcnV6w3OJqJ6TzCCESBVahf5297GEI-OYhHmU_v51eLs7y8x_fl4sv57mq2jrmvGNNqxXvUHc9cK0oq1KsN_sp6nQor3umWYW9KLlCTbFouOhEKUTLOiiPsuWOVzu4kpM3I_g76cDIbcH5lQQfjRpQct5UqEVL26apSgatpkwJ2ipQuqraPnF93nFNczeiVmijh-EZ6fMXa9Zy5a6loEzQukkEHx4IvPs9Y4hyNEHhMIBFNwfJSp7EC9FsoO__g1652du0qg1K1FVaBE8otkMp70Lw2D-KKajc2FDubCiTDeXWhvI2Nb17OsZjyz_flX8B1jDeTA
CitedBy_id crossref_primary_10_1016_j_canlet_2021_08_005
crossref_primary_10_1080_14737140_2024_2350105
crossref_primary_10_3389_fendo_2022_1035929
crossref_primary_10_3390_curroncol28060412
crossref_primary_10_1186_s13058_023_01694_5
crossref_primary_10_1186_s40780_023_00314_w
crossref_primary_10_1007_s10549_023_06864_9
Cites_doi 10.1001/jamaoncol.2016.1897
10.1093/annonc/mdu455
10.1158/0008-5472.CAN-09-4373
10.1016/j.ejca.2016.09.024
10.1158/1078-0432.CCR-17-1960
10.1186/s13058-015-0605-0
10.18632/oncotarget.7753
10.1210/mend.13.6.0308
10.7554/eLife.02907
10.1158/1078-0432.CCR-12-1420
10.1038/nrc3195
10.1007/978-0-387-69080-3_42
10.18637/jss.v033.i01
10.1093/jnci/djn309
10.1016/S1470-2045(15)00041-8
10.1016/S1470-2045(19)30334-1
10.1056/NEJMoa1111065
10.1056/NEJMoa1111097
10.1093/nar/gkn093
10.1093/annonc/mdx173
10.1093/jnci/92.3.205
10.1016/j.ejca.2019.06.002
10.1158/0008-5472.CAN-07-5654
10.1111/j.1464-410X.2007.06659.x
10.1093/jnci/87.3.213
10.1200/JCO.1998.16.9.3121
10.1016/S1470-2045(12)70209-7
10.1186/s13059-014-0550-8
10.3816/CBC.2010.n.035
10.1016/S1470-2045(15)70137-3
10.1200/JCO.2008.18.8391
10.1038/nrclinonc.2009.63
10.1200/JCO.2014.57.2388
10.1016/j.ccr.2013.08.013
10.1186/s12885-016-2620-7
10.1158/0008-5472.CAN-2879-2
10.1016/S0092-8674(00)80108-7
10.1158/1078-0432.CCR-12-3029
10.1073/pnas.200377097
10.1007/s10549-011-1918-z
10.1158/1078-0432.CCR-16-3206
10.1073/pnas.1101747108
10.1161/01.ATV.21.1.6
10.1200/JCO.2015.66.1595
10.1056/NEJMoa040766
10.1093/annonc/mdy448
10.1158/1078-0432.CCR-04-0378
10.1200/JCO.2000.18.7.1423
10.1007/s10549-016-3889-6
ContentType Journal Article
Copyright 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2020
Copyright_xml – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2020
CorporateAuthor Translational Breast Cancer Research Consortium (TBCRC)
on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
CorporateAuthor_xml – name: Translational Breast Cancer Research Consortium (TBCRC)
– name: on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
DBID NPM
AAYXX
CITATION
3V.
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13058-020-01258-x
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Databases
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1465-542X
EndPage 22
ExternalDocumentID oai_doaj_org_article_5584ed790988432a9d02c709cacd449f
10_1186_s13058_020_01258_x
32070401
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P50 CA089019
– fundername: NCI NIH HHS
  grantid: P30 CA013148
– fundername: ;
  grantid: P50CA089019
– fundername: ;
  grantid: IIR13265422
GroupedDBID ---
04C
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABUWG
ACGFO
ACGFS
ACJQM
ACMJI
ACPRK
ACRMQ
ADBBV
ADFRT
ADINQ
ADUKV
AENEX
AFKRA
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BMSDO
BPHCQ
BVXVI
C24
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EIHBH
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
ICW
IHR
INH
INR
ITC
KQ8
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
U2A
UKHRP
WOQ
AAYXX
AFPKN
CITATION
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c496t-5b289dc5bedbfa5dc024fa56040116666056f2d24ef735ced0e1857b737792ba3
IEDL.DBID RPM
ISSN 1465-542X
1465-5411
IngestDate Tue Oct 22 15:13:22 EDT 2024
Tue Sep 17 20:50:14 EDT 2024
Sat Oct 26 00:02:00 EDT 2024
Thu Oct 10 17:36:54 EDT 2024
Thu Sep 12 18:41:13 EDT 2024
Wed Oct 16 00:46:20 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Postmenopausal
Preoperative therapy
Hormone receptor-positive breast cancer
Breast cancer
Letrozole
Bevacizumab
Luminal breast cancer
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c496t-5b289dc5bedbfa5dc024fa56040116666056f2d24ef735ced0e1857b737792ba3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ORCID 0000-0002-9919-2748
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027068/
PMID 32070401
PQID 2357640245
PQPubID 2034567
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_5584ed790988432a9d02c709cacd449f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7027068
proquest_miscellaneous_2358577788
proquest_journals_2357640245
crossref_primary_10_1186_s13058_020_01258_x
pubmed_primary_32070401
PublicationCentury 2000
PublicationDate 2020-02-18
PublicationDateYYYYMMDD 2020-02-18
PublicationDate_xml – month: 02
  year: 2020
  text: 2020-02-18
  day: 18
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Breast cancer research : BCR
PublicationTitleAlternate Breast Cancer Res
PublicationYear 2020
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References H Buteau-Lozano (1258_CR9) 2002; 62
DW Davis (1258_CR35) 2004; 64
M Martin (1258_CR38) 2015; 33
A Lucci (1258_CR49) 2012; 13
MD Mueller (1258_CR10) 2000; 97
LM Spring (1258_CR32) 2016; 2
RK Jain (1258_CR48) 2009; 6
1258_CR17
X Ji (1258_CR56) 2014; 3
GT Williams (1258_CR53) 2012; 12
AK Cheung (1258_CR51) 2011; 108
HM Earl (1258_CR39) 2015; 16
HM Earl (1258_CR43) 2017; 28
K Johnson (1258_CR29) 2015; 17
J Friedman (1258_CR28) 2010; 33
Z Nahleh (1258_CR42) 2019; 10
D Miles (1258_CR46) 2017; 70
WJ Allard (1258_CR19) 2004; 10
SM Hyder (1258_CR8) 2000; 60
BS Roberts (1258_CR22) 2015; 43
CX Ma (1258_CR33) 2017; 23
A Bastide (1258_CR54) 2008; 36
ZA Nahleh (1258_CR41) 2016; 158
HT Zhang (1258_CR2) 1995; 87
A Forero-Torres (1258_CR15) 2010; 10
V Marcel (1258_CR55) 2013; 24
W Shi (1258_CR52) 2016; 7
M Martin (1258_CR37) 2019; 117
HD Bear (1258_CR44) 2015; 16
Z Qu (1258_CR4) 2008; 68
P Therasse (1258_CR16) 2000; 92
P Cottu (1258_CR34) 2018; 29
HS Rugo (1258_CR21) 2011; 134
L Mulrane (1258_CR30) 2012; 18
B Linderholm (1258_CR13) 2000; 18
MN Dickler (1258_CR36) 2016; 34
JA Garcia (1258_CR20) 2007; 99
G von Minckwitz (1258_CR45) 2014; 25
SK Choi (1258_CR50) 2016; 16
BP Schneider (1258_CR47) 2013; 19
M Cristofanilli (1258_CR18) 2004; 351
BS Roberts (1258_CR26) 2018; 24
DW Losordo (1258_CR6) 2001; 21
MJ Ellis (1258_CR24) 2008; 100
JA Foekens (1258_CR12) 2001; 61
B Linderholm (1258_CR14) 1998; 16
MP Pinto (1258_CR5) 2010; 70
MI Love (1258_CR27) 2014; 15
MP Applanat (1258_CR11) 2008; 617
1258_CR25
P Guo (1258_CR3) 2003; 63
SM Hyder (1258_CR7) 1999; 13
HD Bear (1258_CR40) 2012; 366
D Hanahan (1258_CR1) 1996; 86
J Baselga (1258_CR23) 2009; 27
G von Minckwitz (1258_CR31) 2012; 366
References_xml – volume: 2
  start-page: 1477
  issue: 11
  year: 2016
  ident: 1258_CR32
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2016.1897
  contributor:
    fullname: LM Spring
– volume: 25
  start-page: 2363
  issue: 12
  year: 2014
  ident: 1258_CR45
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdu455
  contributor:
    fullname: G von Minckwitz
– volume: 70
  start-page: 2655
  issue: 7
  year: 2010
  ident: 1258_CR5
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-4373
  contributor:
    fullname: MP Pinto
– volume: 70
  start-page: 146
  year: 2017
  ident: 1258_CR46
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2016.09.024
  contributor:
    fullname: D Miles
– volume: 61
  start-page: 5407
  issue: 14
  year: 2001
  ident: 1258_CR12
  publication-title: Cancer Res
  contributor:
    fullname: JA Foekens
– volume: 24
  start-page: 2092
  issue: 9
  year: 2018
  ident: 1258_CR26
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-1960
  contributor:
    fullname: BS Roberts
– volume: 17
  start-page: 94
  year: 2015
  ident: 1258_CR29
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-015-0605-0
  contributor:
    fullname: K Johnson
– volume: 7
  start-page: 18906
  issue: 14
  year: 2016
  ident: 1258_CR52
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.7753
  contributor:
    fullname: W Shi
– volume: 13
  start-page: 806
  issue: 6
  year: 1999
  ident: 1258_CR7
  publication-title: Mol Endocrinol (Baltimore)
  doi: 10.1210/mend.13.6.0308
  contributor:
    fullname: SM Hyder
– volume: 3
  start-page: e02907
  year: 2014
  ident: 1258_CR56
  publication-title: Elife.
  doi: 10.7554/eLife.02907
  contributor:
    fullname: X Ji
– volume: 18
  start-page: 6702
  issue: 24
  year: 2012
  ident: 1258_CR30
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-1420
  contributor:
    fullname: L Mulrane
– volume: 12
  start-page: 84
  issue: 2
  year: 2012
  ident: 1258_CR53
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3195
  contributor:
    fullname: GT Williams
– volume: 617
  start-page: 437
  year: 2008
  ident: 1258_CR11
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-0-387-69080-3_42
  contributor:
    fullname: MP Applanat
– volume: 33
  start-page: 1
  issue: 1
  year: 2010
  ident: 1258_CR28
  publication-title: J Stat Softw
  doi: 10.18637/jss.v033.i01
  contributor:
    fullname: J Friedman
– volume: 100
  start-page: 1380
  issue: 19
  year: 2008
  ident: 1258_CR24
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn309
  contributor:
    fullname: MJ Ellis
– volume: 16
  start-page: 1037
  issue: 9
  year: 2015
  ident: 1258_CR44
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(15)00041-8
  contributor:
    fullname: HD Bear
– ident: 1258_CR25
  doi: 10.1016/S1470-2045(19)30334-1
– volume: 10
  start-page: 357
  issue: 3
  year: 2019
  ident: 1258_CR42
  publication-title: Mol Clin Oncol
  contributor:
    fullname: Z Nahleh
– volume: 366
  start-page: 299
  issue: 4
  year: 2012
  ident: 1258_CR31
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1111065
  contributor:
    fullname: G von Minckwitz
– ident: 1258_CR17
– volume: 366
  start-page: 310
  issue: 4
  year: 2012
  ident: 1258_CR40
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1111097
  contributor:
    fullname: HD Bear
– volume: 36
  start-page: 2434
  issue: 7
  year: 2008
  ident: 1258_CR54
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkn093
  contributor:
    fullname: A Bastide
– volume: 28
  start-page: 1817
  issue: 8
  year: 2017
  ident: 1258_CR43
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx173
  contributor:
    fullname: HM Earl
– volume: 92
  start-page: 205
  issue: 3
  year: 2000
  ident: 1258_CR16
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.3.205
  contributor:
    fullname: P Therasse
– volume: 117
  start-page: 91
  year: 2019
  ident: 1258_CR37
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2019.06.002
  contributor:
    fullname: M Martin
– volume: 68
  start-page: 6232
  issue: 15
  year: 2008
  ident: 1258_CR4
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-5654
  contributor:
    fullname: Z Qu
– volume: 99
  start-page: 519
  issue: 3
  year: 2007
  ident: 1258_CR20
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2007.06659.x
  contributor:
    fullname: JA Garcia
– volume: 87
  start-page: 213
  issue: 3
  year: 1995
  ident: 1258_CR2
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/87.3.213
  contributor:
    fullname: HT Zhang
– volume: 16
  start-page: 3121
  issue: 9
  year: 1998
  ident: 1258_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1998.16.9.3121
  contributor:
    fullname: B Linderholm
– volume: 13
  start-page: 688
  issue: 7
  year: 2012
  ident: 1258_CR49
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(12)70209-7
  contributor:
    fullname: A Lucci
– volume: 43
  start-page: e145
  issue: 21
  year: 2015
  ident: 1258_CR22
  publication-title: Nucleic Acids Res
  contributor:
    fullname: BS Roberts
– volume: 15
  start-page: 550
  issue: 12
  year: 2014
  ident: 1258_CR27
  publication-title: Genome Biol
  doi: 10.1186/s13059-014-0550-8
  contributor:
    fullname: MI Love
– volume: 10
  start-page: 275
  issue: 4
  year: 2010
  ident: 1258_CR15
  publication-title: Clin Breast Cancer
  doi: 10.3816/CBC.2010.n.035
  contributor:
    fullname: A Forero-Torres
– volume: 16
  start-page: 656
  issue: 6
  year: 2015
  ident: 1258_CR39
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(15)70137-3
  contributor:
    fullname: HM Earl
– volume: 27
  start-page: 2630
  issue: 16
  year: 2009
  ident: 1258_CR23
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.8391
  contributor:
    fullname: J Baselga
– volume: 6
  start-page: 327
  issue: 6
  year: 2009
  ident: 1258_CR48
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2009.63
  contributor:
    fullname: RK Jain
– volume: 33
  start-page: 1045
  issue: 9
  year: 2015
  ident: 1258_CR38
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.2388
  contributor:
    fullname: M Martin
– volume: 24
  start-page: 318
  issue: 3
  year: 2013
  ident: 1258_CR55
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.08.013
  contributor:
    fullname: V Marcel
– volume: 16
  start-page: 570
  year: 2016
  ident: 1258_CR50
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2620-7
  contributor:
    fullname: SK Choi
– volume: 64
  start-page: 4601
  issue: 13
  year: 2004
  ident: 1258_CR35
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-2879-2
  contributor:
    fullname: DW Davis
– volume: 86
  start-page: 353
  issue: 3
  year: 1996
  ident: 1258_CR1
  publication-title: Cell.
  doi: 10.1016/S0092-8674(00)80108-7
  contributor:
    fullname: D Hanahan
– volume: 19
  start-page: 1281
  issue: 5
  year: 2013
  ident: 1258_CR47
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-3029
  contributor:
    fullname: BP Schneider
– volume: 97
  start-page: 10972
  issue: 20
  year: 2000
  ident: 1258_CR10
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.200377097
  contributor:
    fullname: MD Mueller
– volume: 134
  start-page: 13
  issue: 1
  year: 2011
  ident: 1258_CR21
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-011-1918-z
  contributor:
    fullname: HS Rugo
– volume: 23
  start-page: 4055
  issue: 15
  year: 2017
  ident: 1258_CR33
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-16-3206
  contributor:
    fullname: CX Ma
– volume: 108
  start-page: 8390
  issue: 20
  year: 2011
  ident: 1258_CR51
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1101747108
  contributor:
    fullname: AK Cheung
– volume: 21
  start-page: 6
  issue: 1
  year: 2001
  ident: 1258_CR6
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.21.1.6
  contributor:
    fullname: DW Losordo
– volume: 62
  start-page: 4977
  issue: 17
  year: 2002
  ident: 1258_CR9
  publication-title: Cancer Res
  contributor:
    fullname: H Buteau-Lozano
– volume: 34
  start-page: 2602
  issue: 22
  year: 2016
  ident: 1258_CR36
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.66.1595
  contributor:
    fullname: MN Dickler
– volume: 351
  start-page: 781
  issue: 8
  year: 2004
  ident: 1258_CR18
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa040766
  contributor:
    fullname: M Cristofanilli
– volume: 60
  start-page: 3183
  issue: 12
  year: 2000
  ident: 1258_CR8
  publication-title: Cancer Res
  contributor:
    fullname: SM Hyder
– volume: 63
  start-page: 4684
  issue: 15
  year: 2003
  ident: 1258_CR3
  publication-title: Cancer Res
  contributor:
    fullname: P Guo
– volume: 29
  start-page: 2334
  issue: 12
  year: 2018
  ident: 1258_CR34
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy448
  contributor:
    fullname: P Cottu
– volume: 10
  start-page: 6897
  issue: 20
  year: 2004
  ident: 1258_CR19
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0378
  contributor:
    fullname: WJ Allard
– volume: 18
  start-page: 1423
  issue: 7
  year: 2000
  ident: 1258_CR13
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2000.18.7.1423
  contributor:
    fullname: B Linderholm
– volume: 158
  start-page: 485
  issue: 3
  year: 2016
  ident: 1258_CR41
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-016-3889-6
  contributor:
    fullname: ZA Nahleh
SSID ssj0017858
Score 2.3958318
Snippet In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with...
Abstract Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is...
Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with...
BACKGROUNDIn preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is associated with...
Abstract Background In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-positive breast cancer is...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 22
SubjectTerms Angiogenesis
Antitumor activity
Bevacizumab
Biopsy
Blood
Breast cancer
Cancer therapies
Consent
Disease
Endocrine therapy
ErbB-2 protein
Estrogens
Headache
Hormone receptor-positive breast cancer
Hypotheses
Immunotherapy
Letrozole
Luminal breast cancer
Lymphatic system
Magnetic resonance imaging
Mammography
Medical research
Monoclonal antibodies
Patients
Post-menopause
Preoperative therapy
Progesterone
Proteinuria
Remission
Ribonucleic acid
RNA
Surgery
Targeted cancer therapy
Toxicity
Tumors
Ultrasonic imaging
Urine
Vascular endothelial growth factor
Womens health
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLaZM-3KZlCqWXRqxXliW5t2RJ2BTSQ0ggN6OXswu79rKPkuxPza_JSPYu2VLopScby4-x9WkemvEnQr7mOjfMmoxWzhSU-5DfxWiZSiG9qJxjxoYfnC9-ieE1_3mT3zxZ6ivUhLX0wO2H6-VoIb2TRVooxTOmC5cyK9PCaus4L6qofdNiE0x1-QOpcrX5RUaJ3gI1da5oCJVQIePe3Y4Zimz9f3Mx_6yUfGJ6zl6Rl53PCMetrK_JM1_vk4PjGuPl6T18g1jFGafH98nziy5ZfkAerk4GlwNAZfQDNMxGaK_g_PwI0Dq5Zjpee3cEYfEsikDwE4jrd0BTwWzu8XDLCA7YrfNm3Uw8hBlbaOZx26yWYPxvbcfr1VQbGNcwaxahYB1j8NUC7xOZHdpr0HGf3INra_q8A_RHbz2wXgYjdJib2gNqXT_D4J-2JWT4WBQRhqeXjNb-thXEhOr5JdiA0vkbcn12ejUY0m4pB2p5IZYUAaEKZ3Pjnal07iy6BrgVqEL6IXGJQZWomGPcVzLLrXepDyRVRgY-RGZ09pbs1SjQewKCm9yjn6R4X3OOAZGRumDS-jA3g85HQr5veractYwdZYx0lChbHJSIgzLioLxLyEno_O2ZgW07HkAMlh0Gy39hMCGHG-iUnQpYlIFHSPCQ2U7Il20zDt6QkdG1b1bxHHxLKZVKyLsWaVtJMobaGD9PQuQOBndE3W2px6NIEC5TJlOhPvyPd_tIXrA4bhjtq0Oyt5yv_Cf0w5bmcxxyj62NMv8
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BkRAXBC1QQ0GDhLjQVeP12mtzQW3UKkUqh6qVcrO8DyeREq9xHNTmp_JrmF07gSDEyZbtJBPPN7Pz2hlCPsRFLJmSES21zCg3Lr-L3jIViTBJqTWTym1wvvqWjG7513E87gNuy76scqMTvaLWVrkY-Ylry5Jwlyj8Un-nbmqUy672IzQekkchGySupEuMtw6XGzyfdruLYhrzMNxsmkmTkyXq7jilznlCFY1ndzsLk-_f_y-j8-_ayT8Wo4tn5GlvRcJpx_bn5IGp9snBaYUe9OIePoKv6_QB833y-KpPnx-Qnzdnw-shoHr6DAXUU1zB4PLyGHC90nYxWxt9DG6cFkVomDn4iR5gS6gbg5e7HuGAjG7s2s4NuBgu2MYf7aoFaX4UarZeLQoJswpqu3Ql7OiVr5b4Pb7XQ_cZNOXn96C7Kj-jAS3UiQF2EsEUTWhbGUA9bOrWNrQrKsOfRRJhdH7NaGUmHSHS1dO3oBxumxfk9uL8Zjii_XAHqniWtBQhkmZaxdJoWRaxVshaPCaoVEKXykQ3KymZZtyUIoqV0QPj2lZJ4TokMllEL8lehQQdEki4jA1aTikPC87RRZKiyJhQxkVr0BwJyKcNZ_O66-GRe98nTfIOBzniIPc4yO8CcuaYv33S9d_2F2wzyXtxzmO024wW2SBLUx6xItMDpsQgU4XSnGdlQI420Ml7pbDMf0M4IO-3t1GcXY6mqIxd-WfwXwqRpgF51SFtS0nEUD_j6wmI2MHgDqm7d6rZ1LcMFwMmUD5e_5-sN-QJ8xLBaJgekb22WZm3aHO18p0XrF8gSCzK
  priority: 102
  providerName: ProQuest
Title TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/32070401
https://www.proquest.com/docview/2357640245
https://search.proquest.com/docview/2358577788
https://pubmed.ncbi.nlm.nih.gov/PMC7027068
https://doaj.org/article/5584ed790988432a9d02c709cacd449f
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6SFEovpU36UJuaKZReGsX2aqWVeouNg1NwCCYB04vQPmQbbEnIcmn8U_trOruSTF166sUyennMfjM7szP7DSGf_MQXVArPTZWIXKZNfhejZZcHXAepUlRIs8F5chuMH9i3mT87In67F8YW7UuxvMxW68tsubC1lcVadts6se7dZMgxluoFYfeYHCNA2xC9SR3w0DblRAvguz7r99udMmHQ3aDB9kPXRExol_GbYaH2KKKeNU1h2onJ8vf_y-n8u3byj8no-gV53niRcFVL-5Ic6eyUnF1lGEGvH-Ez2LpOu2B-Sp5OmvT5Gfl1PxhOh4Dm6SskUCxwBoObmwvA-Url6-VOqwsw7bRchIZege3oAXkKRanxdM0RDjjQZb7LVxrMGi7kpT3m2wqE_pHI5W67TgQsMyjyjSlhx6h8u8H3WK6H-hl05VePoOoqP60APdS5Btr1YIEudJ5pQDusiyov3bqoDH8WRYTxaErdTM9rQYSpp69AGtyWr8jD9eh-OHab5g6uZFFQuQiRMFLSF1qJNPGVRGcBj4EZCpPKxDArSKmiTKfc86VWPW1oqwQ3DIlUJN5rcpKhQG8JBEz4Gj2nkPUTxjBEEjyJKJfarNagO-KQL-3IxkXN4RHb2CcM4hoSMUIitpCIfzpkYAZ_f6fh37Yn8nIeNyiMffTbtOJRLwpD5tEkUj0qeS-SiVSMRalDzlvoxI1R2MSGWShgJtftkI_7y6jOJkeTZDrf2nvwX3Iehg55UyNtL0mLVIfwAwweiHp4BTXIUoY3GvPuv598T55RqzfU7Yfn5KQqt_oDumOV6KASzniHPBmMbu-mHbuogZ_TwfeOVczfDxo6OQ
link.rule.ids 230,315,730,783,787,867,888,2109,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dj9JAEN_oXaK-GL3Ts3rqmBhfvA2w3XZbX8xBuIAexJC75N6a7keBBFosYO74U_1rnN0WFGN8KmkLDMzsb-ervyHkfZAGkinp00zLmHJj67sYLVMRChNmWjOp7APOg2HYu-ZfboKbOuG2rNsqt5jogFoXyubIG5aWJeS2UPh58Z3aqVG2ulqP0LhPDi1VFQZfh-3u8NtoV0cQkZvQiXAQ0IC3WtvHZqKwsUT0DiJqwycEaXx1u7c1OQb_f7mdf3dP_rEdXTwhj2s_Es4rxT8l90x-RI7Pc4yh53fwAVxnp0uZH5EHg7qAfkx-XrU7ow4gQH2CFBYT3MOg3z8D3LF0MZ9ujD4DO1CLonGYGbiZHlBksCgNnq5YwgFVXRabYmbAZnGhKN2xWK9Amh-pmm7W81TCNIdFsbRN7BiXr5f4OY7toXoPOvOzO9BVn5_RgD7q2ABr-DBBJ7rIDSASm8WqKGnVVoZfiyJCrztiNDfjShBpO-pXoKzlls_I9UX3qtOj9XgHqngcrigaSRRrFUijZZYGWqFy8RgirLRsMRMDrTBjmnGTCT9QRjeNJa6SwnIkMpn6z8lBjgK9IBByGRj0nSLeSjnHIEmKNGZCGZuvQYfEIx-3mk0WFYtH4qKfKEwqO0jQDhJnB8mtR9pW-bs7LQO3O1GU46Re0EmAnpvRIm7GUcR9lsa6yZRoxipVmvM488jp1nSSGhaWyW8j9si73WVc0LZKk-amWLt78FcKEUUeOaksbSeJzxCh8e_xiNizwT1R96_k04kjDRdNJpph9PL_Yr0lD3tXg8vksj_8-oo8Ym51MNqKTsnBqlyb1-iBreSbepn9An4oMSA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkSouPFoogQKDhLhQx8lm7bW5taFRAqSqqlaquFjeh5OIxLYcB9H8VH4Ns2s7aipOPTmy1_Gs_M3szM74G0I-erEnqBQ9J1EidJg2-V2Mlh3uc-0nSlEhzQfO4zN_eMW-XXvXt1p92aJ9KWbtdL5op7Opra3MF9Jt6sTc83GfYyzV8QM3V4n7kDxCne34TaBeJxB4YFtzoh3wHI91u833MoHvLtFse4Fj4ia0zvjLcFH3KGKf1a1hmuXJsvj_z_W8W0F5a0kaPCU_m8lUlSi_2qtStOX6Ds_jvWb7jDypHVU4roY8Jw90ukf2j1MM0hc38Als6ajdk98ju-M6Q79P_l6e9C_6gBbwC8SQT3GRhNHoCHBJVNlittbqCEzHLgfRp-dgm4ZAlkBeaDxd0ZADYqnI1tlcg9kmhqywx2xVgtC_YzlbrxaxgFkKebY0VfIY-K-W-D-WTqK6B6OF-Q2oqpBQK0AneKKBuj2YopeepRrQ1Ou8zAqnqlvDx6KIMDy9oE6qJ5UgwpTslyCNahQvyNXg9LI_dOr-EY5koV86iMIgVNITWokk9pREfwSPvnnPJluKkZyfUEWZTnjPk1p1tGHGEtyQMFIR916SnRQFekXAZ8LT6JwFrBszhlGY4HFIudRmQwg9nhb53MAmyiuakMiGV4EfVXiLEG-RxVv0p0VODLI2Iw3Ftz2RFZOofvWRh66hVjzshEHAejQOVYdK3gllLBVjYdIihw0uo9ruLCNDXuQzk05vkQ-by2gxTBooTnW2smNwlpwHQYscVDDeSNKoQYvwLYBvibp9BWFrWclrmL6-953vye7510H0Y3T2_Q15TK1-UqcbHJKdsljpt-j8leKdVfN_m2paKA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TBCRC+002%3A+a+phase+II%2C+randomized%2C+open-label+trial+of+preoperative+letrozole+with+or+without+bevacizumab+in+postmenopausal+women+with+newly+diagnosed+stage+2%2F3+hormone+receptor-positive+and+HER2-negative+breast+cancer&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Vaklavas%2C+Christos&rft.au=Roberts%2C+Brian+S&rft.au=Varley%2C+Katherine+E&rft.au=Lin%2C+Nancy+U&rft.date=2020-02-18&rft.eissn=1465-542X&rft.volume=22&rft.issue=1&rft.spage=22&rft.epage=22&rft_id=info:doi/10.1186%2Fs13058-020-01258-x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon